The Inflation Reduction Act (IRA) will make arguably the most significant changes to U.S. prescription drug pricing regulations ever, but certainly since the creation of the Medicaid Drug Rebate Program in 1990. For the first time, the federal government will directly regulate the price of prescription drugs in Medicare and indirectly limit the ability of drug manufacturers to increase wholesale prices. At the same time, the legislation makes major changes to the Medicare Part D prescription drug benefit, including creating, for the first time, an out-of-pocket cap on annual drug costs.

In a new webinar, Manatt will guide you through the IRA’s drug pricing provisions to help you prepare your organization for a radically different market environment. Click here to register free. Key topics covered will include:

• The new Medicare drug negotiation provisions and the mechanics of their operation
• Medicare inflationary rebates, including critical last-minute changes in scope
• The new Part D benefit design
• The timing of implementation
• The opportunities for public input and judicial review

Even if you can’t make our live program on August 23, click here to register free now and you will receive a link to view the program on demand.

Speakers:

• Alex Dworkowitz, Partner, Manatt Health
• Adam Finkelstein, Counsel, Manatt Health
• Ian Spatz, Senior Advisor, Manatt Health

CLE

This program has been approved for 1.0 NY CLE Professional Practice (transitional and non-transitional) credit and for 1.0 CA MCLE General credit.

If you would like to receive an audio transcript of this webinar due to accessibility issues, please email us at webinars@manatt.com.